Association between human leukocyte antigen polymorphism and human papillomavirus 16-positive vulval intraepithelial neoplasia in british women

Polymorphisms in human leukocyte antigen (HLA) genes have been implicated in the risk for developing human papillomavirus (HPV)-associated cervical neoplasia. By comparison with local cadaver controls typed for HLA class I (n = 946) and II (n = 144) antigens, HPV-16-positive high grade vulval intrae...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2003-01, Vol.63 (2), p.400-403
Main Authors: DAVIDSON, Emma J, DAVIDSON, Judith A, STERLING, Jane C, BALDWIN, Peter J. W, KITCHENER, Henry C, STERN, Peter L
Format: Article
Language:English
Subjects:
Biological and medical sciences
Biopsy
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
HLA-A Antigens - genetics
HLA-DR Antigens - genetics
Humans
Medical sciences
Papillomaviridae - classification
Papillomavirus Infections - genetics
Papillomavirus Infections - immunology
Papillomavirus Infections - pathology
Polymorphism, Genetic
Tumor Virus Infections - genetics
Tumor Virus Infections - immunology
Tumor Virus Infections - pathology
Tumors
Vulvar Neoplasms - genetics
Vulvar Neoplasms - immunology
Vulvar Neoplasms - pathology
Vulvar Neoplasms - virology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Polymorphisms in human leukocyte antigen (HLA) genes have been implicated in the risk for developing human papillomavirus (HPV)-associated cervical neoplasia. By comparison with local cadaver controls typed for HLA class I (n = 946) and II (n = 144) antigens, HPV-16-positive high grade vulval intraepithelial neoplasia patients (n = 42) showed significantly different frequencies of HLA-A2 [odds ratio (OR), 2.1; confidence interval (CI), 1.4-3.9], HLA-B7 (OR, 2.6; CI, 1.4-4.7), HLA-DRB1*01(01/02/04) (OR, 0.1; CI, 0.03-0.5), HLA-DRB1*11 (OR, 3.3; CI, 1.4-7.1), HLA-DRB1*13 (OR, 0), HLA-DQB1*05 (OR, 0.2; CI, 0.05-0.6), and HLA-DQB1*03032 (OR, 4.6; CI, 1.5-14.0). With the exception of HLA-B7 and HLA-DRB1*11, these significant differences were also seen comparative to local HPV-16-positive cervical carcinoma patients (n = 114), suggesting a specific immunogenetic contribution that is independent of HPV-16 infection in high-grade vulval intraepithelial neoplasia. Such factors are important to the development of HPV vaccines for treatment of cervical and vulval neoplasia.
ISSN:0008-5472
1538-7445